Ignite Creation Date:
2024-05-05 @ 5:01 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00374010
Status:
COMPLETED
Last Update Posted:
2017-05-31
First Post:
2006-09-06
Brief Title:
Improving Patient-clinician Communication About End-of-life Care
Sponsor:
University of Pittsburgh
Organization:
University of Pittsburgh
Study Overview
Official Title:
Improving Patient-clinician Communication Among End-stage Renal Disease African Patients and Their Families
Status:
COMPLETED
Status Verified Date:
2008-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The specific aims are
1 to evaluate the feasibility and acceptability of PC-ACP among African American patients with End-stage Renal Disease and their surrogates and
2 to examine preliminary effects of PC-ACP on patient and surrogate outcomes patients perceived quality of communication surrogates level of comfort in decision making for the patient patients difficulty in making choices patient-surrogate congruence in goals of care and patients and surrogates psychosocialspiritual receptiveness at one week following receipt of the intervention
1 to evaluate the feasibility and acceptability of PC-ACP among African American patients with End-stage Renal Disease and their surrogates and
2 to examine preliminary effects of PC-ACP on patient and surrogate outcomes patients perceived quality of communication surrogates level of comfort in decision making for the patient patients difficulty in making choices patient-surrogate congruence in goals of care and patients and surrogates psychosocialspiritual receptiveness at one week following receipt of the intervention
Detailed Description:
Despite the increasing emphasis placed on patient-clinician communication about end of life care efforts to guide the patient to make an informed end-of-life treatment decision often fail Past efforts to enhance end-of-life discussions were insufficient to create treatment decisions that were consistent with the patients values and the surrogates ability to make end-of-life decisions for hisher loved one when required The importance of effective end-of-life discussions has been documented extensively yet systematic explorations of the effects of such dialogue with African Americans are nearly absent from the literature The proposed study is designed to test the ability of an hour-long intervention Patient-Centered Advance Care Planning PC-ACP to enhance clinicians communication about end-of-life care with patients and surrogates The specific aims are 1 to evaluate the feasibility and acceptability of PC-ACP among African American patients with End-stage Renal Disease and their surrogates and 2 to examine preliminary effects of PC-ACP on patient and surrogate outcomes patients perceived quality of communication surrogates level of comfort in decision making for the patient patients difficulty in making choices patient-surrogate congruence in goals of care and patients and surrogates psychosocialspiritual receptiveness at one week following receipt of the intervention A randomized controlled pre and post study will be conducted Subjects patient-surrogate dyads will be randomized to PC-ACP or to a usual care control group Data to assess feasibility clinical and sociodemographic data and baseline measures of patient and surrogate outcomes will be collected when subjects enter the study Measures of the patient and surrogate outcomes and data to assess acceptability of the intervention will be administered at one week follow up Findings from this study are critical to strengthening PC-ACP and designing a randomized controlled trial to test its efficacy for improving the quality of patient-clinician communication and the quality of decision making for future medical care with African American patients in comparison with non-Hispanic Whites
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None